Abstract
The Nomura Research Group is focused on developing and applying chemoproteomic platforms to drug the undruggable proteome to develop next‐generation disease therapies. One of the greatest challenges that we face in discovering new disease therapies is that most proteins are considered “undruggable” or difficult to target with small‐molecules. Our research group addresses this challenge by developing chemoproteomic platforms to discover and pharmacologically target unique and novel therapeutic druggable hotspots for disease therapy. We currently have four major research directions. Our first research area focuses on coupling phenotypic screening of fragment‐based covalent ligand libraries with chemoproteomic platforms to rapidly discover novel druggable hotspots, targets, and small‐molecule leads for disease therapy. Our second research area focuses on covalent ligand discovery against druggable hotspots targeted by covalently‐acting natural products that show therapeutic activity using chemoproteomic platforms to discover new therapeutic targets and synthetically tractable therapies for cancer. Our third research area focuses on advancing chemoproteomic technologies to map and pharmacologically target druggable hotspots for targeted protein degradation. Our fourth research area focuses on using chemoproteomic platforms to map on and off‐targets of environmental and pharmaceutical chemicals towards discovering new toxicological mechanisms. Our fifth research area focuses on using chemoproteomic and metabolomic platforms to discover unique and novel metabolic drivers of cancer. The talk will highlight key examples of these themes within our lab.Support or Funding InformationNational Institutes of Health (R01CA172667, P42ES004705) and Novartis Institutes for BioMedical ResearchThis abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
